← All Salarius Pharmaceuticals, INC filings

Salarius Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

SLRX
Salarius Pharmaceuticals, INC
10-K/A: Decoy Therapeutics Files Amended 10-K with Governance Details
Decoy Therapeutics Inc. has filed an amendment to its 2025 Annual Report on Form 10-K, primarily to include previously omitted Part III information regarding directors, executive compensation, and corporate governance.
SLRX
Salarius Pharmaceuticals, INC
10-K: Decoy Therapeutics Navigates Nasdaq Listing, Advances AI-Driven Pipeline
Decoy Therapeutics Inc. reports a significant net loss for 2025, addresses Nasdaq delisting concerns with a reverse stock split, and advances its AI-driven peptide conjugate pipeline following a strategic merger.
SLRX
Salarius Pharmaceuticals, INC
10-K: Salarius Pharmaceuticals Faces Going Concern Uncertainty Amidst Proposed Merger with Decoy Therapeutics
Salarius Pharmaceuticals reports a net loss for 2024 and expresses substantial doubt about its ability to continue as a going concern, while pursuing a merger with Decoy Therapeutics to address its financial challenges.
SLRX
Salarius Pharmaceuticals, INC
10-K/A: Salarius Pharmaceuticals Files Amended 10-K to Include Omitted Information
Salarius Pharmaceuticals has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and corporate governance.
SLRX
Salarius Pharmaceuticals, INC
10-K: Salarius Pharmaceuticals Faces Going Concern Uncertainty Amid Strategic Review
Salarius Pharmaceuticals reports a net loss of $12.5 million for 2023 and expresses substantial doubt about its ability to continue as a going concern without additional funding or a strategic transaction.